Amoxicillin - high dose dual therapy — Competitive Intelligence Brief

Amoxicillin - high dose dual therapy (Amoxicillin - high dose dual therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious Disease.

phase 1 Beta-lactam antibiotic Penicillin-binding proteins Infectious Disease Small molecule

Target snapshot

Amoxicillin - high dose dual therapy (Amoxicillin - high dose dual therapy) — Unidade Local de Saúde do Alto Ave, EPE. Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicillin - high dose dual therapy TARGET	Amoxicillin - high dose dual therapy	Unidade Local de Saúde do Alto Ave, EPE	phase 1	Beta-lactam antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Quick response: Amoxicillin for 5 days	Quick response: Amoxicillin for 5 days	University Hospital, Montpellier	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs)
Concomitant therapy 10 days	Concomitant therapy 10 days	Incheon St.Mary's Hospital	marketed	Beta-lactam antibiotic	Penicillin-binding proteins
Oral amoxicillin	Oral amoxicillin	Boston Medical Center	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Amoxicillin Capsules	Amoxicillin Capsules	The Third Xiangya Hospital of Central South University	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
amoxicillin and metronidazole	amoxicillin and metronidazole	University of Campinas, Brazil	marketed	Combination antibiotic (beta-lactam + nitroimidazole)	Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic class)

1. Pfizer · 2 drugs in this class
2. Bayer · 1 drug in this class
3. Belén Retamal-Valdes · 1 drug in this class
4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
6. Incheon St.Mary's Hospital · 1 drug in this class
7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
9. National Taiwan University Hospital · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class